1. Home
  2. KXIN vs KALA Comparison

KXIN vs KALA Comparison

Compare KXIN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$4.61

Market Cap

4.7M

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.60

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
KALA
Founded
2015
2009
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
KXIN
KALA
Price
$4.61
$0.60
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
1.5M
21.5M
Earning Date
01-01-0001
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$0.61
52 Week High
$75.00
$20.60

Technical Indicators

Market Signals
Indicator
KXIN
KALA
Relative Strength Index (RSI) 64.63 34.58
Support Level $3.32 $0.67
Resistance Level $5.40 $0.86
Average True Range (ATR) 0.85 0.24
MACD 0.14 0.07
Stochastic Oscillator 78.25 0.16

Price Performance

Historical Comparison
KXIN
KALA

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: